EX-FILING FEES 3 ex107.htm

 

Exhibit 107

 

Calculation of Filing Fee Tables

 

S-1

…………..

(Form Type)

 

CytRx Corporation

……………………………………………………..…

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered and Carry Forward Securities

 

  

Security

Type

 

Security

Class

Title

  

Fee

Calculation

or Carry

Forward

Rule

  

Amount

Registered

  

Proposed

Maximum

Offering

Price Per

Unit

  

Maximum

Aggregate

Offering

Price(1)(2)

  

Fee

Rate

  

Amount of

Registration

Fee

 
Newly Registered Securities  
Fees Previously Paid  Equity   Common Stock, par value $0.001 per share    457(c)   20,727,274(3)  $ 0.425    $ 8,809,091.45    0.0000927   $ 816.60  
Carry Forward Securities 
                                       
   Total Offering Amounts       $ 8,809,091.45        $ 816.60  
   Total Fees Previously Paid               $1,705.05 
   Total Fee Offsets                $1,705.05 
   Net Fee Due                $0.00 

 

(1) Pursuant to Rule 416 under the Securities Act of 1933, as amended, the registrant is also registering an indeterminate amount of additional shares of the registrant’s common stock that become issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration, and the shares of common stock set forth in this table shall be adjusted to include such shares, as applicable.
   
(2) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) under the Securities Act, based on the average of the high and low prices of the common stock as reported on The OTC Markets on March 22, 2022, of $0.425 per share
   
(3) Comprised of (i) 9,363,637 shares of common stock that may be sold by the selling stockholder named in the registration statement (the “registration statement”) to which this exhibit relates upon the conversion of shares of Series C Preferred Stock of CytRx Corporation, and (ii) 11,363,637 shares of common stock of CytRx Corporation that may be sold by the selling stockholder named in the registration statement upon the exercise of the Preferred Investment Options (as defined in the registration statement).